{"doi":"10.1016/j.esmorc.2025.100055","title":"IMMUNOSARC2 (COHORT 7A): A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF EPIRUBICIN AND IFOSFAMIDE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)","abstract":"unified cohort of 134 patients was formed using tissue microarrays from two sarcoma centers: 109 cases from MD Anderson Cancer Center and 25 from Fred Hutchinson Cancer Center (FHCC).Two mIHC panels were used: CD4, CD68/CD163, CD8, FoxP3, PD-1, PD-L1 (with post-mIHC ERG DAB) and CD68, CD20, CD3, CD163, CD206, CD34.Transcriptomic analysis was performed using the NanoString IO 360 panel on 25 angiosarcoma samples from FHCC with 9 hemangiomas as controls. Results:We observed significant differences in immune cell infiltration between cutaneous and non-cutaneous angiosarcomas, with higher levels of CD20+ B-cells (p=0.015),CD3+ T-cells (p=0.007),CD8+ T-cells (p< 0.001), FOXP3+ regulatory Tcells (p< 0.001), PD1+ cells (p=0.004) and CD4+ T-cells (p=0.015) in cutaneous tumors.Survival analysis demonstrated that higher CD20+ B-cell infiltration was significantly associated with improved overall survival (p=0.014).Gene expression analysis revealed higher MAPK pathway-related transcripts including MAP4K2 and MAPKAPK2 in angiosarcomas.Angiosarcomas also had higher complement levels (C5/C6), and lower expression of interleukin 1 receptor antagonist (IL1RN).When comparing angiosarcoma subtypes, scalp/face tumors showed distinctive immune profiles with lower complement expression and higher expression of inflammatory markers S100A8, S100A9, NOD2, and IL1B; paired with higher CD3+ and CD4+ cell infiltration on mIHC compared to other sites. Conclusion:These findings provide insights into the immunological landscape of angiosarcomas across different anatomical locations.The significantly higher immune infiltration in cutaneous versus non-cutaneous angiosarcomas suggests distinct immunological mechanisms, consistent with higher immunotherapy responsiveness in cutaneous angiosarcomas.Our results suggest that immune cell infiltration, particularly CD20+ B-cells, may serve as prognostic biomarkers in this rare disease.","journal":"ESMO rare cancers.","year":2025,"id":585974,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":0.0,"corpus_rank":10062,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.9264,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1500126,"name":"Javier Martinez-Trufero","orcid":null,"position":1,"is_corresponding":false},{"id":1500127,"name":"Robertodiaz Beveridge","orcid":null,"position":2,"is_corresponding":false},{"id":1500128,"name":"Irenecarrasco Garcia","orcid":null,"position":3,"is_corresponding":false},{"id":1500129,"name":"David S. da Silva Moura","orcid":null,"position":4,"is_corresponding":false},{"id":1500130,"name":"Ana Sebio García","orcid":null,"position":5,"is_corresponding":false},{"id":1500131,"name":"Enriquegonzalez Billalabeitia","orcid":null,"position":6,"is_corresponding":false},{"id":1500132,"name":"Rafaelramos Asensio","orcid":null,"position":7,"is_corresponding":false},{"id":1500133,"name":"Antonio Gutierrez","orcid":null,"position":8,"is_corresponding":false},{"id":214129,"name":"Josefina Cruz","orcid":null,"position":9,"is_corresponding":false},{"id":260071,"name":"Claudia Valverde","orcid":"0000-0003-4107-8616","position":10,"is_corresponding":false},{"id":1500134,"name":"Patricio Ledesma","orcid":null,"position":11,"is_corresponding":false},{"id":260053,"name":"Nadia Hindi","orcid":"0000-0002-5864-762X","position":12,"is_corresponding":false},{"id":1500125,"name":"Javier Martín-Broto","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:59:24.273134Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}